Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol (2014) 5.89

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49

Cancer Statistics, 2017. CA Cancer J Clin (2017) 4.77

A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science (2002) 4.21

Adenoviruses as vaccine vectors. Mol Ther (2004) 3.09

Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther (1990) 3.04

CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response. J Exp Med (1996) 2.21

Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther (1998) 1.51

Platelet-derived CD154 enables T-cell priming and protection against Listeria monocytogenes challenge. Blood (2008) 1.40

Breaking tolerance in cancer immunotherapy: time to ACT. Curr Opin Immunol (2005) 1.20

Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res (2014) 1.08

Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer (2007) 1.06

Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inserts. J Immunotoxicol (2008) 1.01

Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res (2009) 1.01

Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol (2001) 1.00

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget (2016) 0.97

10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. Gene Ther (2011) 0.96

Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol (2012) 0.93

Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. Vaccine (2006) 0.93

Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer. Cell Immunol (2015) 0.91

Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Immunotherapy (2011) 0.84

Tolerance and immune suppression in the tumor microenvironment. Cell Immunol (2015) 0.84

Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy. J Immunotoxicol (2014) 0.82

Immunotherapy for prostate cancer: False promises or true hope? Cancer (2016) 0.78

[Breaking immune tolerance in cancer]. Bull Cancer (2015) 0.77

Can Prostate Cancer Really Respond to Immunotherapy? J Clin Oncol (2016) 0.77

Breakthrough of immune self-tolerance to calreticulin induced by CpG-oligodeoxynucleotides as adjuvant. Fukushima J Med Sci (2007) 0.77

CD40 ligand-expressing recombinant vaccinia virus promotes the generation of CD8(+) central memory T cells. Eur J Immunol (2015) 0.76